标题
Umbralisib: First Approval
作者
关键词
-
出版物
DRUGS
Volume 81, Issue 7, Pages 857-866
出版商
Springer Science and Business Media LLC
发表日期
2021-04-02
DOI
10.1007/s40265-021-01504-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
- (2021) Nathan H. Fowler et al. JOURNAL OF CLINICAL ONCOLOGY
- The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells
- (2020) Kamira Maharaj et al. Blood Advances
- Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy
- (2020) Anthony R. Mato et al. BLOOD
- Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
- (2019) Loretta J Nastoupil et al. Lancet Haematology
- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- UMBRALISIB AND CARFILZOMIB POTENTLY INHIBIT CAP DEPENDENT TRANSLATION IN LYMPHOMA
- (2019) I. Pal et al. HEMATOLOGICAL ONCOLOGY
- PHASE I/II STUDY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB (TG-1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION
- (2019) A.R. Mato et al. HEMATOLOGICAL ONCOLOGY
- A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
- (2019) M. Lunning et al. HEMATOLOGICAL ONCOLOGY
- Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- (2019) Matthew Lunning et al. BLOOD
- Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
- (2018) Howard A Burris et al. LANCET ONCOLOGY
- Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
- (2018) Matthew S Davids et al. Lancet Haematology
- The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest
- (2016) S L Locatelli et al. LEUKEMIA
- Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies
- (2014) E. Jabbour et al. HAEMATOLOGICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started